BACTERIA-ENGINEERED TO ELICIT ANTIGEN-SPECIFIC T-CELLS
Provided are modified microorganisms, such as live recombinant commensal bacteria, that express a heterologous antigen, and methods of using the modified microorganisms to induce an antigen-specific immune response to the heterologous antigen. The modified microorganism can be used to induce a regulatory T cell immune response to the heterologous antigen to treat an autoimmune disease in a subject in need thereof, or can be used to induce an effector T cell immune response to the heterologous antigen to treat a proliferative disease in a subject in need thereof..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 25. Okt. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
FISCHBACH MICHAEL A [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-10-25, Last update posted on www.tib.eu: 2024-03-05, Last updated: 2024-03-08 |
|---|
| Patentnummer: |
EP3986451 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA014698226 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA014698226 | ||
| 003 | DE-627 | ||
| 005 | 20240308101059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA014698226 | ||
| 035 | |a (EPA)EP3986451 | ||
| 035 | |a (EPA)74037327 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a FISCHBACH MICHAEL A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a BACTERIA-ENGINEERED TO ELICIT ANTIGEN-SPECIFIC T-CELLS |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-10-25, Last update posted on www.tib.eu: 2024-03-05, Last updated: 2024-03-08 | ||
| 520 | |a Provided are modified microorganisms, such as live recombinant commensal bacteria, that express a heterologous antigen, and methods of using the modified microorganisms to induce an antigen-specific immune response to the heterologous antigen. The modified microorganism can be used to induce a regulatory T cell immune response to the heterologous antigen to treat an autoimmune disease in a subject in need thereof, or can be used to induce an effector T cell immune response to the heterologous antigen to treat a proliferative disease in a subject in need thereof. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a NAGASHIMA KAZUKI |4 aut | |
| 700 | 0 | |a CHEN YIYIN E |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 25. Okt. |
| 773 | 1 | 8 | |g year:2023 |g day:25 |g month:10 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/74037327/publication/EP3986451A1?q=EP3986451 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 25 |c 10 | ||